Nanexa AB

NEW
FRA:40M (Sweden)  
€ 0.55 +0.14 (+33.98%) Sep 1
At Loss
P/B:
8.29
Market Cap:
€ 102.31M ($ 118.41M)
Enterprise V:
€ 97.66M ($ 113.03M)
Volume:
1.00K
Avg Vol (2M):
550.00
Trade In:
Volume:
1.00K
At Loss

Business Description

Description
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
Name Current Vs Industry Vs History
Cash-To-Debt
66.11
Equity-to-Asset
0.86
Debt-to-Equity
0.01
Debt-to-EBITDA
-0.09
Piotroski F-Score
4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
27.99
Distress
Grey
Safe
Beneish M-Score
-2.8
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate
55
3-Year EPS without NRI Growth Rate
60.8
3-Year FCF Growth Rate
43.8
3-Year Book Growth Rate
-33.8
Name Current Vs Industry Vs History
5-Day RSI
90
9-Day RSI
83.94
14-Day RSI
79.79
3-1 Month Momentum %
-15.52
6-1 Month Momentum %
1.86
12-1 Month Momentum %
97.62

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
2.89
Quick Ratio
2.89
Cash Ratio
2.5
Days Sales Outstanding
67.4

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-47.5
Shareholder Yield %
-5.97
Name Current Vs Industry Vs History
Gross Margin %
152.64
Operating Margin %
-67.39
Net Margin %
-72.54
EBITDA Margin %
-27.59
FCF Margin %
-99.16
OCF Margin %
-18.64
ROE %
-23.22
ROA %
-17.54
ROIC %
-21.47
3-Year ROIIC %
1956.04
ROC (Joel Greenblatt) %
-207.08
ROCE %
-19.45

Nanexa AB Filings

Filing Date Document Date Form
No Filing Data

Nanexa AB Stock Events

Financials Calendars
Event Date Price (€)
Fourth quarter earnings results for 2026 2027-02-19 In 170 days
Third quarter earnings results for 2026 2026-10-21 In 49 days
Second quarter earnings conference call for 2026 2026-08-27 13:00 0.39 (+0.00%)
Second quarter earnings results for 2026 2026-08-27 0.39 (+0.00%)
General meeting for 2025 2026-05-12 15:00 0.31 (+0.00%)
First quarter earnings results for 2026 2026-04-29 0.33 (+0.00%)
Annual report for 2025 2026-03-26 0.30 (+0.00%)
Fourth quarter earnings results for 2025 2026-02-19 0.31 (+0.00%)
Third quarter earnings results for 2025 2025-10-21 0.16 (+0.00%)
Second quarter earnings results for 2025 2025-08-27 0.17 (+0.00%)
Show
Entries

Press Release

Subject Date
No Press Release

Articles on Nanexa AB

No articles.